Wardhani Shinta Oktya, Fajar Jonny Karunia, Nurarifah Nina, Hermanto Djoko Heri, Fatonah Siti, Djajalaksana Susanthy, Fatoni Arie Zainul, Arsana Putu Moda, Wulandari Laksmi, Soegiarto Gatot, Dhama Kuldeep, Harapan Harapan
Division of Hematology and Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia.
Brawijaya Internal Medicine Research Center, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia.
Clin Epidemiol Glob Health. 2021 Jul-Sep;11:100763. doi: 10.1016/j.cegh.2021.100763. Epub 2021 May 10.
Recent evidence suggested that the higher titers of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody from convalescent plasma donors contributed to the clinical improvement in coronavirus disease 2019 (COVID-19) patients. However, the titers of -SARS-CoV-2 antibodies varied in each individual, and the precise factors that might govern such variation have not been elucidated.
To assess the factors associated with high titers of -SARS-CoV-2 antibody among COVID-19 convalescent plasma (CCP) donors.
A cross-sectional study was conducted in Saiful Anwar General Hospital, Malang, Indonesia. Information of interest including demographic characteristics, clinical symptoms, comorbidities, laboratory findings, and the titers of -SARS-CoV-2 antibody among COVID-19 CCP donors were collected. The correlation was assessed using multiple logistic regression.
A total of 50 COVID-19 CCP donors with the titers of -SARS-CoV-2 antibody of more than 1:320 and 33 donors with the titers of less than 1:320 were analyzed. Our analysis revealed that CCP donors with history of cough, fever, dyspnea, and pneumonia significantly had higher titers of -SARS-CoV-2 antibody compared to asymptomatic donors. Moreover, CCP donors with elevated levels of eosinophils and immature granulocytes and low levels of albumins had higher levels of -SARS-CoV-2 antibody. The titer of antibody was not affected by comorbidities of donors.
CPP donors who had experience of symptomatic COVID-19 with high eosinophils level, high immature granulocytes and low albumin level have higher titers of -SARS-COV-2 antibody than those who experienced asymptomatic COVID-19. Our current findings may be used as the additional baseline criteria for selecting the donors of CCP for the management of COVID-19.
近期证据表明，康复期血浆捐献者中抗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗体的较高滴度有助于2019冠状病毒病（COVID-19）患者的临床改善。然而，SARS-CoV-2抗体的滴度在个体之间存在差异，而可能控制这种差异的精确因素尚未阐明。
评估COVID-19康复期血浆（CCP）捐献者中与高滴度SARS-CoV-2抗体相关的因素。
在印度尼西亚马朗的赛富安瓦尔综合医院进行了一项横断面研究。收集了包括人口统计学特征、临床症状、合并症、实验室检查结果以及COVID-19 CCP捐献者中SARS-CoV-2抗体滴度等相关信息。使用多元逻辑回归评估相关性。
共分析了50名SARS-CoV-2抗体滴度大于1:320的COVID-19 CCP捐献者和33名滴度小于1:320的捐献者。我们的分析显示，有咳嗽、发热、呼吸困难和肺炎病史的CCP捐献者与无症状捐献者相比，SARS-CoV-2抗体滴度显著更高。此外，嗜酸性粒细胞和未成熟粒细胞水平升高且白蛋白水平较低的CCP捐献者，其SARS-CoV-2抗体水平更高。抗体滴度不受捐献者合并症的影响。
有症状COVID-19经历、嗜酸性粒细胞水平高、未成熟粒细胞水平高且白蛋白水平低的CPP捐献者，其SARS-CoV-2抗体滴度高于无症状COVID-19经历者。我们目前的发现可作为选择CCP捐献者以管理COVID-19的额外基线标准。
